Salim Syed
Stock Analyst at Mizuho
(2.33)
# 2,676
Out of 5,090 analysts
76
Total ratings
42.62%
Success rate
0.65%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Salim Syed
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ASMB Assembly Biosciences | Maintains: Outperform | $29 → $40 | $35.01 | +14.25% | 2 | Nov 20, 2025 | |
| NKTX Nkarta | Maintains: Outperform | $16 → $14 | $1.80 | +677.78% | 8 | Jun 10, 2025 | |
| CYTK Cytokinetics | Maintains: Outperform | $103 → $84 | $65.67 | +27.91% | 7 | May 29, 2025 | |
| BIIB Biogen | Maintains: Outperform | $207 → $169 | $181.30 | -6.78% | 16 | May 7, 2025 | |
| AMGN Amgen | Maintains: Neutral | $235 → $280 | $329.89 | -15.12% | 8 | May 7, 2025 | |
| GILD Gilead Sciences | Maintains: Outperform | $100 → $117 | $121.22 | -3.48% | 7 | May 5, 2025 | |
| WVE Wave Life Sciences | Maintains: Outperform | $19 → $22 | $7.49 | +193.72% | 5 | Nov 21, 2024 | |
| PCVX Vaxcyte | Maintains: Outperform | $113 → $163 | $46.48 | +250.69% | 3 | Sep 10, 2024 | |
| ATRA Atara Biotherapeutics | Upgrades: Outperform | $25 → $18 | $14.33 | +25.61% | 4 | Aug 16, 2024 | |
| ELVN Enliven Therapeutics | Initiates: Buy | $34 | $21.81 | +55.89% | 1 | Apr 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $82 → $99 | $56.88 | +74.05% | 3 | Mar 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $60 → $53 | $73.64 | -28.03% | 7 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $28 → $21 | $1.20 | +1,650.00% | 5 | Nov 16, 2022 |
Assembly Biosciences
Nov 20, 2025
Maintains: Outperform
Price Target: $29 → $40
Current: $35.01
Upside: +14.25%
Nkarta
Jun 10, 2025
Maintains: Outperform
Price Target: $16 → $14
Current: $1.80
Upside: +677.78%
Cytokinetics
May 29, 2025
Maintains: Outperform
Price Target: $103 → $84
Current: $65.67
Upside: +27.91%
Biogen
May 7, 2025
Maintains: Outperform
Price Target: $207 → $169
Current: $181.30
Upside: -6.78%
Amgen
May 7, 2025
Maintains: Neutral
Price Target: $235 → $280
Current: $329.89
Upside: -15.12%
Gilead Sciences
May 5, 2025
Maintains: Outperform
Price Target: $100 → $117
Current: $121.22
Upside: -3.48%
Wave Life Sciences
Nov 21, 2024
Maintains: Outperform
Price Target: $19 → $22
Current: $7.49
Upside: +193.72%
Vaxcyte
Sep 10, 2024
Maintains: Outperform
Price Target: $113 → $163
Current: $46.48
Upside: +250.69%
Atara Biotherapeutics
Aug 16, 2024
Upgrades: Outperform
Price Target: $25 → $18
Current: $14.33
Upside: +25.61%
Enliven Therapeutics
Apr 9, 2024
Initiates: Buy
Price Target: $34
Current: $21.81
Upside: +55.89%
Mar 6, 2024
Maintains: Buy
Price Target: $82 → $99
Current: $56.88
Upside: +74.05%
Mar 5, 2024
Maintains: Buy
Price Target: $60 → $53
Current: $73.64
Upside: -28.03%
Nov 16, 2022
Maintains: Buy
Price Target: $28 → $21
Current: $1.20
Upside: +1,650.00%